NR4A1 and breast cancer: Similarly, capivasertib had high activity in patients with ctDNA-identified AKT1 mutations, both in hormone-receptor-positive BC with fulvestrant and in hormone-receptor-negative BC as a single agent, confirming the results of a previous phase I study [176].